L. Geoffrois

3.4k total citations
55 papers, 1.2k citations indexed

About

L. Geoffrois is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, L. Geoffrois has authored 55 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Pulmonary and Respiratory Medicine, 24 papers in Oncology and 20 papers in Surgery. Recurrent topics in L. Geoffrois's work include Head and Neck Cancer Studies (18 papers), Renal cell carcinoma treatment (10 papers) and Lung Cancer Treatments and Mutations (8 papers). L. Geoffrois is often cited by papers focused on Head and Neck Cancer Studies (18 papers), Renal cell carcinoma treatment (10 papers) and Lung Cancer Treatments and Mutations (8 papers). L. Geoffrois collaborates with scholars based in France, Belgium and Switzerland. L. Geoffrois's co-authors include Jean Bourhis, Frédéric Rolland, Gwénaëlle Gravis, Christine Chevreau, M. Lapeyre, Christian Borel, B. Toussaint, Armelle Caty, Bernard Escudier and Sylvie Négrier and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

L. Geoffrois

54 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
L. Geoffrois France	20	555	519	435	420	358	55	1.2k
Iris Gluck Israel	15	307 0.6×	634 1.2×	303 0.7×	369 0.9×	142 0.4×	26	1.0k
Voichita Bar‐Ad United States	21	447 0.8×	514 1.0×	273 0.6×	281 0.7×	330 0.9×	98	1.4k
Mary Ellyn Witt United States	17	552 1.0×	607 1.2×	710 1.6×	997 2.4×	237 0.7×	24	1.5k
Mei‐Kim Ang Singapore	19	473 0.9×	658 1.3×	319 0.7×	411 1.0×	372 1.0×	64	1.3k
K.K. Ang United States	15	508 0.9×	580 1.1×	390 0.9×	340 0.8×	302 0.8×	59	1.4k
Lester Peters Australia	19	310 0.6×	368 0.7×	497 1.1×	571 1.4×	225 0.6×	25	1.2k
Raffaele Cavina Italy	18	728 1.3×	549 1.1×	340 0.8×	124 0.3×	158 0.4×	53	1.2k
Javier Martínez‐Trufero Spain	20	1.1k 2.1×	976 1.9×	533 1.2×	519 1.2×	199 0.6×	124	2.0k
Yeon‐Sil Kim South Korea	22	705 1.3×	546 1.1×	454 1.0×	507 1.2×	173 0.5×	110	1.6k
Meng‐Zhong Liu China	22	723 1.3×	495 1.0×	785 1.8×	597 1.4×	316 0.9×	51	1.7k

Countries citing papers authored by L. Geoffrois

Since Specialization

Citations

This map shows the geographic impact of L. Geoffrois's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L. Geoffrois with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L. Geoffrois more than expected).

Fields of papers citing papers by L. Geoffrois

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by L. Geoffrois. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L. Geoffrois. The network helps show where L. Geoffrois may publish in the future.

Co-authorship network of co-authors of L. Geoffrois

This figure shows the co-authorship network connecting the top 25 collaborators of L. Geoffrois. A scholar is included among the top collaborators of L. Geoffrois based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with L. Geoffrois. L. Geoffrois is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Péré, Hélène, Jérôme Fayette, L. Geoffrois, et al.. (2022). 653O Neoadjuvant nivolumab (N) before chemoradiation (CRT) in high-risk HPV driven oropharynx cancer (OPC) - IMMUNEBOOST-HPV: A multicenter randomized phase II trial. Annals of Oncology. 33. S840–S841. 5 indexed citations

Oudard, Stéphane, Gwénaëlle Gravis, F. Kleinclauss, et al.. (2021). Cost-effectiveness Analysis of Innovative Therapy for Patients with Newly Diagnosed Hormone-Sensitive Metastatic Prostate Cancer. Clinical Genitourinary Cancer. 19(5). e326–e333. 11 indexed citations

Gross‐Goupil, Marine, Aude Fléchon, Loı̈c Mourey, et al.. (2021). 670P Cabozantinib associated with concomitant radiotherapy or a bone targeted agent (multimodal approach, results from the CABOREAL study post-hoc analysis). Annals of Oncology. 32. S694–S695. 1 indexed citations

Dalban, Cécile, Brigitte Laguerre, Sylvain Ladoire, et al.. (2020). 712P Primary tumour response in patients treated with nivolumab for metastatic renal cell carcinoma (mRCC): Results of the GETUG-AFU 26 NIVOREN trial. Annals of Oncology. 31. S560–S561. 1 indexed citations

Bourhis, Jean, Clément Sire, Yungan Tao, et al.. (2020). LBA38 Pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC): Results of the GORTEC 2015-01 “PembroRad” randomized trial. Annals of Oncology. 31. S1168–S1168. 46 indexed citations

Pointreau, Y., M. Alfonsi, C. Sire, et al.. (2020). Induction chemotherapy followed by cisplatin or cetuximab concomitant to radiotherapy for laryngeal/hypopharyngeal cancer: Long-term results of the TREMPLIN randomised GORTEC trial. European Journal of Cancer. 133. 86–93. 15 indexed citations

Négrier, Sylvie, Céline Ferlay, Marine Gross‐Goupil, et al.. (2020). Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II AXIPAP trial. European Journal of Cancer. 129. 107–116. 45 indexed citations

Troussier, I., G. Klausner, P Giraud, et al.. (2018). Évolutions dans la prise en charge des métastases ganglionnaires cervicales sans cancer primitif retrouvé : doses et volumes cibles de la radiothérapie avec modulation d’intensité. Cancer/Radiothérapie. 22(5). 438–446. 3 indexed citations

Tao, Yungan, Anne Aupérin, P. Gräff, et al.. (2017). Very accelerated radiotherapy or concurrent chemoradiotherapy for N3 head and neck squamous cell carcinoma: Pooled analysis of two GORTEC randomized trials. Oral Oncology. 71. 61–66. 10 indexed citations

10.

Pouessel, Damien, Sylvie Chevret, Frédéric Rolland, et al.. (2015). Standard or accelerated methotrexate, vinblastine, doxorubicin and cisplatin as neoadjuvant chemotherapy for locally advanced urothelial bladder cancer: Does dose intensity matter?. European Journal of Cancer. 54. 69–74. 11 indexed citations

11.

Fizazi, Karim, Gwénaëlle Gravis, L. Geoffrois, et al.. (2014). Combining gemcitabine, cisplatin, and ifosfamide (GIP) is active in patients with relapsed metastatic germ-cell tumors (GCT): a prospective multicenter GETUG phase II trial. Annals of Oncology. 25(5). 987–991. 40 indexed citations

12.

Bourhis, Jean, M. Lapeyre, J. Tortochaux, et al.. (2011). Accelerated radiotherapy and concomitant high dose chemotherapy in non resectable stage IV locally advanced HNSCC: Results of a GORTEC randomized trial. Radiotherapy and Oncology. 100(1). 56–61. 18 indexed citations

13.

Jankowski, R., Philippe Henrot, Cédric Baumann, et al.. (2009). CT Assessment of Woodworkers’ Nasal Adenocarcinomas Confirms the Origin in the Olfactory Cleft. American Journal of Neuroradiology. 30(7). 1440–1444. 20 indexed citations

14.

Culine, Stéphane, Andrew Kramar, Christine Théodore, et al.. (2008). Randomized Trial Comparing Bleomycin/Etoposide/Cisplatin With Alternating Cisplatin/Cyclophosphamide/Doxorubicin and Vinblastine/Bleomycin Regimens of Chemotherapy for Patients With Intermediate- and Poor-Risk Metastatic Nonseminomatous Germ Cell Tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP. Journal of Clinical Oncology. 26(3). 421–427. 59 indexed citations

15.

Sebban, Catherine, Sophie Dussart, Christine Fuhrmann, et al.. (2008). Oral moxifloxacin or intravenous ceftriaxone for the treatment of low-risk neutropenic fever in cancer patients suitable for early hospital discharge. Supportive Care in Cancer. 16(9). 1017–1023. 36 indexed citations

16.

Théodore, Christine, Christine Chevreau, Karim Fizazi, et al.. (2008). A phase II multicenter study of oxaliplatin in combination with paclitaxel in poor prognosis patients who failed cisplatin-based chemotherapy for germ-cell tumors. Annals of Oncology. 19(8). 1465–1469. 9 indexed citations

17.

Fléchon, Aude, Karim Fizazi, S. Gourgou-Bourgade, et al.. (2006). Gemcitabine and cisplatin after radical cystectomy for bladder cancer in an adjuvant setting: feasibility study from the Genito-Urinary Group of the French Federation of Cancer Centers. Anti-Cancer Drugs. 17(6). 705–708. 8 indexed citations

18.

Théodore, Christine, L. Geoffrois, J. B. Vermorken, et al.. (2005). Multicentre EORTC study 16997: Feasibility and phase II trial of farnesyl transferase inhibitor & gemcitabine combination in salvage treatment of advanced urothelial tract cancers. European Journal of Cancer. 41(8). 1150–1157. 43 indexed citations

19.

Ravaud, Alain, Markus Borner, J. H. M. Schellens, et al.. (2001). UFT and leucovorin in first-line chemotherapy for patients with metastatic gastric cancer. An Early Clinical Studies Group (ECSG)/European Organization for Research Treatment of Cancer (EORTC) phase II trial. European Journal of Cancer. 37(13). 1642–1647. 23 indexed citations

20.

Hadjadj, Samy, L. Geoffrois, Aubert, G. Weryha, & J Leclère. (1995). [Thyroid metastases from cancer of the kidney. Two cases].. PubMed. 24(30). 1386–8. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact